ERBB2 and prostate cancer: 17-AAG was shown to radiosensitize prostate cancer and glioma cell lines exhibiting the now familiar molecular signature [20], [33] of depletion of radioresistance markers and HSP90 client proteins AKT, ErbB2 and cRAF [8].